Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

1

Introduction

00:00 • 5min

2

Benetuzumab and the Progression-Free Survival of Patients on the Drug

04:42 • 5min

3

The Effect of Anti-Cd20 on Response Rates in Unmutated CLL Patients

09:25 • 4min

4

The Importance of Comparative Analysis of Targeted Novel Therapies and Relapse Refractory CLL

13:39 • 3min

5

Ibrutinib vs Venetoclax: A Better Approach for Relapse Disease?

16:22 • 3min

6

Venetoclax and Relapse

19:15 • 2min

7

The Future of Triplets and Doublets

20:52 • 5min

8

BTK and Venetoclax: A Comparison

25:35 • 3min

9

Benetuzumab and Benetoclax: A Comparison

28:15 • 1min

10

The Benefits of Getting Off of BTK Inhibitors

29:39 • 5min

11

Ibrutinib and MRD Negative Patients

34:22 • 6min

12

The Tolerance of CANTIVATE in Young Patients

40:12 • 2min

13

The Role of Chlorambusilobenituzumab in CLL Treatment

42:31 • 3min

14

The Misinformation About Chemo-Mutatherapy

45:05 • 2min

15

The Cost of CME for Breast Cancer Treatment

46:39 • 5min

16

Venetoclax-Obenituzumab-Fixed-Based Approaches for CLL

52:09 • 3min

17

The Importance of Quality of Life in Relapsed CLL

55:00 • 5min

18

The Efficacy Advantage of the Dell 17P Drug

01:00:00 • 2min

19

The Effects of the Ibrutinib Trial on Progression-Free Survival

01:01:36 • 2min

20

The Benefits of a Caliber BTK Inhibitor

01:04:04 • 3min

21

Xanu and Calabrutinib: A Comparison

01:07:13 • 4min

22

Vannetoclax: A New BCL2 Inhibitor

01:10:48 • 5min

23

The Role of BTK Inhibitors in CLL T Cell Therapy

01:15:21 • 2min

24

BTK Degraders in CLL and Lymphoma

01:17:44 • 2min